This is a different patient group to us CLLers but the principle would apply across all patient groups and disease types. Funded by the National Institute for Health Research (NIHR) and led by Prof Galina Velikova (medical oncologist University of Leeds and the Leeds Cancer centre), the eRAPID trial set out to establish whether symptom control could be improved using automated advice to improve patients’ wellbeing.
Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online eHealth system for patients to self-report symptoms during cancer treatment.
This trial provides automated severity-dependent patient advice guiding self-management or medical contact and displays the reports in electronic patient records. This trial evaluated the impact of eRAPID on symptom control, healthcare use, patient self-efficacy, and quality of life (QOL) in a patient population treated predominantly with curative intent.
Real-time monitoring with electronic patient-reported outcomes improved physical well-being ( at 6 and 12 weeks) and self-efficacy ( at 18 weeks) in a patient population predominantly treated with curative intent, without increasing hospital workload. Patients reported better symptom control and physical wellbeing in the early weeks of treatment, with the system preventing symptom deterioration in about 9% of patients after 12 weeks.
More here: ascopubs.org/doi/abs/10.120...
Jackie
Better support for soaring numbers of cancer survivors 29 March 2013. Post treatment cancer 'recovery package' urged
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
